Add to Cart View Cart/Checkout More Products

Volume 21, 2017 CD

Six back issues of The International Journal of Pharmaceutical Compounding from 2017 on one convenient CD.
Only $95 per CD.
(Multiple Theme or Library CD orders priced at: 2 to 5 = $85; 6 to 9 = $75; 10 or more = $65 each.)

  • Permanant storage and easy retrieval of IJPC articles, formulations, SOP's and more.
  • Print IJPC articles in color for your marketing needs.

The back issues are stored as a high-resolution, full-color Adobe Portable Document Format (.pdf) file, complete with an electronic Table of Contents.

They may be searched by keyword and printed by the page. Software to read the PDF file is freely available from the Adobe Reader page.

Issues
Volume/IssueDateTitle
Vol. 21 No. 1 January/February 2017 Volume 21, Number 1
Vol. 21 No. 2 March/April 2017 Volume 21, Number 2
Vol. 21 No. 3 May/June 2017 Volume 21, Number 3
Vol. 21 No. 4 July/August 2017 Volume 21, Number 4
Vol. 21 No. 5 September/October 2017 Volume 21, Number 5
Vol. 21 No. 6 November/December 2017 Volume 21, Number 6

Articles
Volume/IssuePageTitle
Vol. 21 No. 1 4 PreScription: Compounding Pharmacy Issues for 2017
Vol. 21 No. 1 6 Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3
Vol. 21 No. 1 19 When to Compound Medications for Veterinary Patients
Vol. 21 No. 1 22 Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications
Vol. 21 No. 1 28 Why You Should Become an International Academy of Compounding Pharmacists Member
Vol. 21 No. 1 31 Analytic Methods Used in Quality Control in a Compounding Pharmacy
Vol. 21 No. 1 39 Basics of Compounding with Dilutions and Concentrates
Vol. 21 No. 1 47 Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms
Vol. 21 No. 1 58 Calculations
Vol. 21 No. 1 60 Clindamycin 10-mg/mL Oral Suspension
Vol. 21 No. 1 61 Diazoxide 10-mg/mL Oral Suspension
Vol. 21 No. 1 62 Infliximab 1% Ophthalmic Solution
Vol. 21 No. 1 63 Nifedipine 0.5% Rectal Ointment
Vol. 21 No. 1 64 Tetracaine Hydrochloride 0.5% Ophthalmic Solution
Vol. 21 No. 1 65 Zonisamide 10-mg/mL Oral Suspension
Vol. 21 No. 1 66 Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate
Vol. 21 No. 1 76 Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Vol. 21 No. 1 83 A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding
Vol. 21 No. 2 92 PreScription: Whatever Happened to Common Sense?
Vol. 21 No. 2 95 U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Vol. 21 No. 2 105 Restructuring the Art of Health by Pharmacists: Formulation Designs with Oral Vehicles--Teaching Pharmacy Students
Vol. 21 No. 2 111 Consultation for Human, Veterinary, and Compounded Medications
Vol. 21 No. 2 116 The International Academy of Compounding Pharmacists Introduces a New President
Vol. 21 No. 2 118 Quality Control: (Material) Safety Data Sheets
Vol. 21 No. 2 127 Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1
Vol. 21 No. 2 133 Accuracy Considerations in Sterile Compounding
Vol. 21 No. 2 144 Calculations
Vol. 21 No. 2 146 Azathioprine 10-mg/mL Oral Suspension
Vol. 21 No. 2 147 Candesartan Cilexetil 8 mg Liquid-Filled Capsules
Vol. 21 No. 2 148 Furosemide 10-mg/mL Oral Suspension
Vol. 21 No. 2 149 Ketoconazole 20-mg/mL Oral Suspension
Vol. 21 No. 2 150 Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers
Vol. 21 No. 2 154 Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date
Vol. 21 No. 2 160 Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Vol. 21 No. 2 164 Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs
Vol. 21 No. 2 171 Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules
Vol. 21 No. 3 180 PreScription: United States Pharmacopeia Chapter <800> Comments and Alternatives
Vol. 21 No. 3 182 Adventures in the Environmental World and Environmental Microbiology Sampling of Air for Pharmaceutical Sterile Compounding
Vol. 21 No. 3 193 Microbiologic Testing for 503A Sterile-Compounding Pharmacies
Vol. 21 No. 3 205 Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report
Vol. 21 No. 3 212 International Academy of Compounding Pharmacists Legislative/Regulatory Update
Vol. 21 No. 3 215 Basics of Compounding: 3D Printing--Pharmacy Applications, Part 2
Vol. 21 No. 3 223 Basics of Sterile Compounding: Manipulating Peptides and Proteins
Vol. 21 No. 3 230 Calculations
Vol. 21 No. 3 232 Candesartan Cilexetil 0.1-mg/mL to 2.0-mg/mL Oral Suspension
Vol. 21 No. 3 233 Ketoconazole 20-mg/mL in SyrSpend SF pH4 Oral Suspension
Vol. 21 No. 3 234 Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base
Vol. 21 No. 3 235 Meloxicam 1% Topical Gel
Vol. 21 No. 3 236 Ofloxacin 0.3% Ophthalmic Solution
Vol. 21 No. 3 237 PVP Iodine 10% Antiseptic Cream
Vol. 21 No. 3 238 Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases
Vol. 21 No. 3 239 Trimethoprim 10-mg/mL Oral Suspension
Vol. 21 No. 3 240 Updated Stability Data for Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil
Vol. 21 No. 3 242 Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats
Vol. 21 No. 3 247 Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance
Vol. 21 No. 3 251 Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes
Vol. 21 No. 3 255 Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions
Vol. 21 No. 4 268 PreScription: Just Think About It!
Vol. 21 No. 4 271 Change Is In the Air: What You Need to Know About Pharmacy Ventilation Under United States Pharmacopeia <800>
Vol. 21 No. 4 277 Component Selection for Sterile Compounding
Vol. 21 No. 4 282 Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas
Vol. 21 No. 4 290 The International Academy of Compounding Pharmacists Applauds the Leadership of Congressmen Griffith and Cuellar in Introducing Bill HR 2871
Vol. 21 No. 4 293 Basics of Compounding: 3D Printing: Pharmacy Applications, Part 3: Compounding, Formulation Considerations, and the Future
Vol. 21 No. 4 301 Basics of Sterile Compounding: Excipients Used in Injections
Vol. 21 No. 4 310 Calculations
Vol. 21 No. 4 312 Betamethasone 0.1% and Neomycin 0.6% Gel-Cream
Vol. 21 No. 4 313 Castor Oil 50% in Modified Pluronic Lecithin Organogel Gel
Vol. 21 No. 4 314 Copper Sulfate, Magnesium Sulfate, Phenylephrine, and Guaifenesin Pluronic Lecithin Organogel
Vol. 21 No. 4 315 Disopyramide 100-mg Capsules
Vol. 21 No. 4 316 Ferrous Sulfate 30-mg Fe/mL Oral Drops
Vol. 21 No. 4 317 Reteplase Injection
Vol. 21 No. 4 318 Sertraline Hydrochloride 10-mg/mL Oral Suspension
Vol. 21 No. 4 319 Tacrolimus 0.06% Ophthalmic Drops
Vol. 21 No. 4 320 Torsemide 10-mg/mL Injection
Vol. 21 No. 4 321 Tranilast 8% Pluronic Lecithin Organogel Gel
Vol. 21 No. 4 322 Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Vol. 21 No. 4 330 Compounded Levofloxacin Triple Therapy is Safe and Effective for Refractory Helicobacter pylori
Vol. 21 No. 4 334 Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt
Vol. 21 No. 4 339 Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4
Vol. 21 No. 4 347 Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia
Vol. 21 No. 5 356 PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Vol. 21 No. 5 358 Compounding Opportunities in Urology
Vol. 21 No. 5 364 Child-safety Containers/Devices and Compounding
Vol. 21 No. 5 373 Documentation: Records and Reports
Vol. 21 No. 5 382 IACP Legislative/Regulatory Update
Vol. 21 No. 5 384 Quality Control: Bar Codes and Bar Code Scanners for Unit-Dose Medications in a Healthcare Setting
Vol. 21 No. 5 388 Basics of Compounding: 3D Printing--Pharmacy Applications: Geometric Shape Effects on 3D Printing
Vol. 21 No. 5 395 Basics of Sterile Compounding: Particulate Matter
Vol. 21 No. 5 406 Calculations
Vol. 21 No. 5 408 Acetylcysteine Solutions for Inhalation
Vol. 21 No. 5 409 Carbamazepine 25-mg/mL in SyrSPend SF pH4 Oral Suspension
Vol. 21 No. 5 410 Etoposide 20-mg/mL Injection
Vol. 21 No. 5 411 Fentanyl Citrate 50-mcg/mL Injection
Vol. 21 No. 5 412 Fluoxymesterone 10-mg Capsules
Vol. 21 No. 5 413 Ioversol Injection
Vol. 21 No. 5 414 Levocarnitine 100-mg/mL Oral Solution
Vol. 21 No. 5 415 Peritoneal Dialysis Solution with 1.5%, 2.5%, or 4.25% Dextrose
Vol. 21 No. 5 416 Tacrolimus 0.3-mg/mL Ophthalmic Solution
Vol. 21 No. 5 417 Vancomycin 50 mg/mL in Oral Syrup Suspension
Vol. 21 No. 5 418 Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Vol. 21 No. 5 426 Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes
Vol. 21 No. 5 430 Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt
Vol. 21 No. 5 436 Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags
Vol. 21 No. 6 444 PreScription: Issues with the NAMS 2017 Hormone Therapy Position Statement
Vol. 21 No. 6 446 Feline Transdermal Formulation Considerations
Vol. 21 No. 6 454 Orodispersible Films for Compounding Pharmacies
Vol. 21 No. 6 463 Features of Pharmaceutical Compounding in the Republic of Tajikistan
Vol. 21 No. 6 468 Join the Partnership for Personalized Prescriptions (P3) Advocacy Effort!
Vol. 21 No. 6 471 Basics of Compounding: Hot Melt Extrusion
Vol. 21 No. 6 481 Basics of Compounding: Compounding Irrigation Solutions for Sterile and Nonsterile Preparations
Vol. 21 No. 6 488 Calculations
Vol. 21 No. 6 490 Amitriptyline 20 mg/mL in OraPlus:OraSweet Suspension
Vol. 21 No. 6 491 Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Vol. 21 No. 6 492 Fluconazole 10% in RECURA Cream
Vol. 21 No. 6 493 Haloperidol 5-mg/mL Injection
Vol. 21 No. 6 494 Hydroxychloroquine Sulfate 25 mg/mL in Oral Mix or Oral Mix SF
Vol. 21 No. 6 495 Promethazine Hydrochloride 12.5 mg/0.1 mL in PLO Gel
Vol. 21 No. 6 496 Spironolactone 5 mg/mL in SuspendIt Oral Suspension
Vol. 21 No. 6 497 Tolmetin 400-mg Capsules
Vol. 21 No. 6 498 Trace Elements Injection 5
Vol. 21 No. 6 499 Vancomycin 5-mg/mL Injection
Vol. 21 No. 6 500 To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid
Vol. 21 No. 6 513 Validation of the Technological Process of the Preparation "Milk by Vidal"
Vol. 21 No. 6 518 Auditing Safety of Compounding and Reconstituting of Intravenous Medicines on Hospital Wards in Finland
Vol. 21 No. 6 530 Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives